Ken W. Marshall is SVP & Chief Commercial Officer at Aquestive Therapeutics, Inc. (AQST). They have made 1 open-market trade across 1 company since 2018, most recently 2023-03-09.
CIK 0001740092
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $15K since 2018, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AQST | 150,000 | $566K |
Shares reported on the most recent Form 4, priced at the 2023-03-09 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AQST | BUY | 2018-11-21 | 2018-12-03 | $10.15 | $15K | -10.1% | -12.7% | -13.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.